Literature DB >> 19806025

p53 negatively regulates expression of FoxM1.

Bulbul Pandit, Marianna Halasi, Andrei L Gartel.   

Abstract

The Forkhead box M1 (FoxM1) oncogenic transcription factor is overexpressed in a majority of human tumors. p53 is a transcription factor and a major tumor suppressor that is mutated in 50% of human cancers. In this study, we compared the levels of FoxM1 in normal BJ human fibroblasts, BJ fibroblasts with p53 knockdown and corresponding BJ immortal/oncogenic cell lines with inactivated p53. We found that partial deletion or inactivation of p53 in these cells leads to upregulation of FoxM1 expression. Similarly, p53 knockdown in several human cancer cell lines with wt-p53 led to upregulation of FoxM1 mRNA and protein expression, while induction of p53 by DNA-damage led to downregulation of FoxM1. These data suggest that p53 negatively regulates FoxM1 expression and therefore inactivation of p53 in tumors could partially explain the phenomenon of FoxM1 overexpression in human cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19806025     DOI: 10.4161/cc.8.20.9628

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  53 in total

1.  Thiostrepton, proteasome inhibitors and FOXM1.

Authors:  Andrei L Gartel
Journal:  Cell Cycle       Date:  2011-12-15       Impact factor: 4.534

2.  Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin.

Authors:  Vladimir Petrovic; Robert H Costa; Lester F Lau; Pradip Raychaudhuri; Angela L Tyner
Journal:  Cancer Biol Ther       Date:  2010-06-06       Impact factor: 4.742

3.  Recovery from a DNA-damage-induced G2 arrest requires Cdk-dependent activation of FoxM1.

Authors:  Mónica Alvarez-Fernández; Vincentius A Halim; Lenno Krenning; Melinda Aprelia; Shabaz Mohammed; Albert J Heck; René H Medema
Journal:  EMBO Rep       Date:  2010-04-09       Impact factor: 8.807

4.  Primate-specific RFPL1 gene controls cell-cycle progression through cyclin B1/Cdc2 degradation.

Authors:  J Bonnefont; T Laforge; O Plastre; B Beck; S Sorce; C Dehay; K-H Krause
Journal:  Cell Death Differ       Date:  2010-08-20       Impact factor: 15.828

5.  FoxM1 is a novel target of a natural agent in pancreatic cancer.

Authors:  Zhiwei Wang; Aamir Ahmad; Sanjeev Banerjee; Asfar Azmi; Dejuan Kong; Yiwei Li; Fazlul H Sarkar
Journal:  Pharm Res       Date:  2010-03-31       Impact factor: 4.200

6.  Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma.

Authors:  Zebin Wang; Yu Zheng; Hyun Jung Park; Jing Li; Janai R Carr; Yi-ju Chen; Megan M Kiefer; Dragana Kopanja; Srilata Bagchi; Angela L Tyner; Pradip Raychaudhuri
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

7.  NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.

Authors:  Mitali Chattopadhyay; Ravinder Kodela; Gabriela Santiago; Thuy Tien C Le; Niharika Nath; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2020-02-14       Impact factor: 5.858

Review 8.  Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis.

Authors:  J Jeffery; D Sinha; S Srihari; M Kalimutho; K K Khanna
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  Proteasome inhibitors suppress the protein expression of mutant p53.

Authors:  Marianna Halasi; Bulbul Pandit; Andrei L Gartel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 10.  FOX(M1) news--it is cancer.

Authors:  Marianna Halasi; Andrei L Gartel
Journal:  Mol Cancer Ther       Date:  2013-02-26       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.